An Introduction to Medicinal Chemistry

Dr Graham L. Patrick gained his BSc Honours at Glasgow University, winning the McKay-Smith Prize for Chemistry. He completed his PhD with Professor Kirby and Professor Robins studying the biosynthesis of gliotoxin and related fungal metabolites. Following this, he worked in the pharmaceutical industry as a research chemist and radiochemist on a variety of projects that included topic areas such as opioids, antibacterial agents and antidepressants. His academic career has included positions at Leeds and Strathclyde Universities as well as the Australian National University. He joined the University of Paisley (now the University of the West of Scotland) in 1990, teaching medicinal chemistry and drug design. Currently, he is an Associate Lecturer with the Open University, an author of scientific textbooks and fiction, and an historical archivist

1: Drugs and Drug Targets 2: Protein Structure and Function 3: Enzymes: Structure and Function 4: Receptors: Structure and Function 5: Receptors and Signal Transduction 6: Nucleic Acids: Structure and Function 7: Enzymes as Drug Targets 8: Receptors as Drug Targets 9: Nucleic Acids as Drug Targets 10: Miscellaneous Drug Targets 11: Pharmacokinetics and Related Topics Case Study 1: Statins 12: Drug Discovery: Finding a Lead 13: Drug Design: Optimizing Target Interactions 14: Drug Design: Optimizing Access to the Target 15: Getting the Drug to Market Case Study 2: The Design of ACE Inhibitors Case Study 3: Artemisinin and Related Antimalarial Drugs Case Study 4: The Design of Oxamni Case Study 5: Fosfidomycin as an Antimalarial Agent 16: Combinatorial and Parallel Synthesis 17: In Silico Drug Design 18: Quantitative Structure-Activity Relationships Case Study 6:  De Novo Design of a Thymidylate Synthase Inhibitor 19: Antibacterial Agents 20: Antiviral Agents 21: Anticancer Agents 22: Protein Kinase Inhibitors as Anticancer Agents 23: Antibodies and Other Biologics 24: Cholinergics, Anticholinergics, and Anticholinestarases 25: Drugs Acting on the Adrenergic Nervous System 26: The Opioid Analgesics 27: Anti-Ulcer Agents 28: Cardiovascular Drugs Case Study 7: Steroidal Anti-Inflammatory Agents Case Study 8: Design of a Novel Antidepressant Case Study 9: The Design and Development Of Aliskiren Case Study 10: Factor Xa Inhibitors Case Study 11: Reversible Inhibitors of HCV NS-34A Protease